In this article, we will list the 5 Best Stocks to Buy in a Rising Market According to Wall Street Analysts. Please visit 10 Best Stocks to Buy in a Rising Market According to Wall Street Analysts if you would like to see the extended list and the methodology behind it.
5. Venture Global, Inc. (NYSE:VG)
Stock Upside Potential: 34.03%
Year to Date Gain: 69.03%
Number of Hedge Fund Holders: 22
Venture Global Inc. (NYSE:VG) is one of the best stocks to buy in a rising market, according to Wall Street analysts. On April 23, Venture Global Inc. (NYSE:VG) subsidiary Venture Global Calcasieu closed a $750 million senior secured note pegged at 6% and due in 2036.
The notes are secured by a first-priority security interest in assets. The company plans to use net proceeds from the offering, along with cash on hand and other funds, to prepay outstanding term loans. Earlier on April 10, Calcasieu Pass Funding entered into a $1.75 billion senior secured term loan B credit facility.
The company used part of the proceeds from the credit facility to redeem in full the preferred equity interests previously issued to Stonepeak Bayou Holdings. The issuance of the $1.75 credit facility significantly reduced the overall cost of capital. It also further strengthened the balance sheet and liquidity position, and underscored Venture Global Inc.’s ability to access the capital markets even in a dynamic environment.
Venture Global, Inc. (NYSE:VG) is a prominent American energy company. It develops, owns, and operates liquefied natural gas (LNG) export facilities using modular technology. This allows production of low-cost LNG from North American natural gas. The company focuses on the entire LNG supply chain, including production, transport, and export.
4. Circle Internet Group Inc. (NYSE:CRCL)
Stock Upside Potential: 38.14%
Year to Date Gain: 20.20%
Number of Hedge Fund Holders: 58
Circle Internet Group Inc. (NYSE:CRCL) is one of the best stocks to buy in a rising market, according to Wall Street analysts. On April 22, Morgan Stanley reiterated an $80 price target and Equal Weight rating on Circle Internet Group Inc. (NYSE:CRCL).
Morgan Stanley maintains an Equal Weight rating on the stock, citing the Decentralized Finance deregulation and industry players’ liability for illegal activity. Recent hacks at KelpDAO, where $290 million was stolen, and Drift Protocol, where $285 million was stolen, underscore headwinds in the industry. Additionally, the sector is under scrutiny as bank lobbying groups remain opposed to stablecoin yields, which they believe will cause deposit flight.
On the other hand, Circle Internet Group launched its Circle Payment Network Management Payments service. The service enabled banks and enterprises to use USDC stablecoin for transactions without directly managing digital assets. It also includes the minting and burning of blockchain infrastructure, allowing partners to interact solely in fiat currency.
Circle Internet Group (NYSE:CRCL) is a financial technology company that provides infrastructure for digital currency and public blockchain, enabling businesses to move money efficiently. It is best known as the principal issuer and operator of USDC, a major dollar-pegged stablecoin, and as a provider of tools for programmable payments and blockchain applications.
3. Summit Therapeutics (NASDAQ:SMMT)
Stock Upside Potential: 42.05%
Year To Date Gain: 26.03%
Number of Hedge Fund Holders: 25
Summit Therapeutics (NASDAQ:SMMT) is one of the best stocks to buy in a rising market, according to Wall Street analysts. On April 21, analysts at Stifel reiterated a Buy rating on Summit Therapeutics (NASDAQ:SMMT) and a $45 price target.
The positive stance comes on the heels of Akeso announcing plans to disclose HARMONi-6 interim Overall Survival readout at ASCO 2026. The disclosure is to optimize the setup better than when HARMONi-2 interim OS was disclosed last year as a result of an NMPA approval.
Unlike Harmoni 2, Harmoni-6 features 33% larger sample size and all-squamous histology. The study provides a first look at an emerging OS from an ivonescimab Phase 3 trial randomized against anti-PD-1 tislelizumab. Last year, HARMONi-2 analyzed ivonescimab against monotherapy pembrolizumab in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).
Akeso is seeking label expansion for Ivonescimab in China, following an interim analysis requested by Chinese health authorities that showed a clinically meaningful positive trend favoring Ivonescimab over Pembrolizumab in PD-L1.
Summit Therapeutics (NASDAQ:SMMT) is a clinical-stage biopharmaceutical company focused on developing novel oncology therapies to treat serious, unmet medical needs. Their primary focus is the development and commercialization of ivonescimab, a potential first-in-class bispecific antibody targeting PD-1 and VEGF for the treatment of non-small cell lung cancer (NSCLC).
2. Applied Digital Corporation (NASDAQ:APLD)
Stock Upside Potential: 42.94%
Year To Date Gain: 24.53%%
Number of Hedge Fund Holders: 40
Applied Digital Corporation (NASDAQ:APLD) is one of the best stocks to buy in a rising market, according to Wall Street analysts. On April 8, Applied Digital Corporation (NASDAQ:APLD) asserted its differentiation in the high-power AI data center industry. The differentiation comes as the company operates the only 100MW direct-to-chip liquid-cooled data center.
The company delivered a 139% increase in fiscal third-quarter revenue to $126.6 million. Amid the robust revenue growth, the net loss attributable to shareholders reported was $100.9 million. The financial results came on the heels of accelerating demand for high-performance AI data center capacity.
In addition, Applied Digital Corp’s data center hosting business, which operates 286 MW of Bitcoin mining capacity, continues to deliver strong results and the highest return on assets. The segment generated $14 million in operating profit and $37.5 million in revenue in the quarter ended February. The solid performance was driven by improvements across data center hosting facilities.
Applied Digital Corporation (NASDAQ:APLD) designs, builds, and operates next-generation data centers and high-performance computing (HPC) infrastructure, primarily serving AI, machine learning, and cloud applications. The company provides turnkey hosting services and GPU-driven cloud services for artificial intelligence, while maintaining infrastructure for blockchain/Bitcoin.
1. ImmunityBio, Inc. (NASDAQ:IBRX)
Stock Upside Potential: 79.21%
Year To Date Gain: 268.32%
Number of Hedge Fund Holders: 19
ImmunityBio, Inc. (NASDAQ:IBRX) is one of the best stocks to buy in a rising market, according to Wall Street analysts. On April 9, ImmunityBio, Inc. (NASDAQ:IBRX) delivered impressive preliminary operational results for its fiscal quarter ending March 31, 2026.
Product revenue in the quarter was up 168% year over year to $44.2 million. The increase comes on the heels of ANKTIVA, an FDA-approved treatment for non-muscle invasive bladder cancer, commercial launch. The significant product revenue builds on 2025 net product revenue of $113 million, a 700% increase over 2024. ImmunityBio exited the quarter with $380.9 million in cash and cash equivalents.
ANKTIVA is the company’s lead product, expected to solidify its revenue base as it has been approved across five jurisdictions representing 34 countries. Its continued momentum underscores growing physician adoption and disciplined commercial execution. Following strong growth in 2025, ImmunityBio is focused on scaling in the US and expanding into global markets to pursue new revenue streams.
ImmunityBio, Inc. (NASDAQ:IBRX) is a clinical-stage biotechnology company focused on developing and commercializing next-generation immunotherapies that activate a patient’s natural killer (NK) cells and T cells to treat cancers and infectious diseases. Its lead FDA-approved drug, ANKTIVA (N-803), is used in combination with BCG to treat non-muscle invasive bladder cancer (NMIBC).
While we acknowledge the potential of IBRX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than IBRX and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 11 Best TSX Stocks to Buy According to Hedge Funds and 8 Best Australian Stocks to Buy in 2026.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email below.
